沙利度胺辅助治疗急性白血病的效果观察
|
摘要
目的探讨沙利度胺辅助治疗急性白血病的临床疗效。方法选取2017年1月至2018年12月本院血液科收治的急性白血病患者94例,按随机数字表法分为观察组和对照组各47例。对照组予以联合化疗,急性粒细胞白血病(AML)患者使用三尖杉酯碱+阿糖胞苷方案(HA),急性淋巴细胞白血病(ALL)患者使用长春新碱+柔红霉素+环磷酰胺+强的松方案(VDCP),此外观察组在此方案的基础上加用沙利度胺辅助治疗。两组治疗时间均为3个月,观察两组患者疗效、白细胞、外周及骨髓幼稚细胞变化及不良反应情况等。结果治疗后观察组总有效率明显高于对照组(P<0.05);治疗后观察组的白细胞、外周及骨髓幼稚细胞3项指标下降程度明显优于对照组(P<0.05);两组不良反应的差异无统计学意义(P>0.05)。结论沙利度胺辅助治疗急性白血病具有显著疗效。
Objective To investigate the clinical efficacy of thalidomide in the adjuvant treatment of acute leukemia. Methods A total of 94 patients with acute leukemia admitted were enrolled in the hospital's hematology department from January 2017 to December 2018. According to the random number table method, they were divided into the observation group(n=47) and the control group(n=47). The control group was given combined chemotherapy: patients with acute myelogenous leukemia(AML)were given harringtonine and cytosine arabinoside(HA), patients with acute lymphoblastic leukemia(ALL) were given vincristine, daunorubicin, cyclophosphamide and prednisone(VDCP). The observation group was supple-mented with adjuvant thalidomide based on the standard chemotherapy regimen. The treatment time of both groups was 3 months. The patient's efficacy, related clinical examination indexes and adverse reactions were observed. Results After treatment, the total effective rate of the observation group was significantly higher than that of control group(P<0.05). After treatment, the levels of leukocytes, peripheral blood immature cells and bone marrow naive cells in the observation group decreased significantly compared with control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Thalidomide has a significant effect in the adjuvant treatment of acute leukemia.
Objective To investigate the clinical efficacy of thalidomide in the adjuvant treatment of acute leukemia. Methods A total of 94 patients with acute leukemia admitted were enrolled in the hospital's hematology department from January 2017 to December 2018. According to the random number table method, they were divided into the observation group(n=47) and the control group(n=47). The control group was given combined chemotherapy: patients with acute myelogenous leukemia(AML)were given harringtonine and cytosine arabinoside(HA), patients with acute lymphoblastic leukemia(ALL) were given vincristine, daunorubicin, cyclophosphamide and prednisone(VDCP). The observation group was supple-mented with adjuvant thalidomide based on the standard chemotherapy regimen. The treatment time of both groups was 3 months. The patient's efficacy, related clinical examination indexes and adverse reactions were observed. Results After treatment, the total effective rate of the observation group was significantly higher than that of control group(P<0.05). After treatment, the levels of leukocytes, peripheral blood immature cells and bone marrow naive cells in the observation group decreased significantly compared with control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Thalidomide has a significant effect in the adjuvant treatment of acute leukemia.
引文
[1] 樊文静,范枝俏.来那度胺在复发难治性血液系统疾病中的研究及应用进展[J].中国实验血液学杂志,2018,26(2):595-599.
[2] 杨海青,邱发麒.沙利度胺对老年急性髓系白血病患者血清碱性成纤维细胞生长因子、血管内皮生长因子水平的影响[J].中国老年学杂志,2018,38(24):5936-5938.
[3] 张之南.血液病诊断与疗效标准[M].3版.北京:科学出版社,2007:103-121.
[4] 祖璎玲,张莉,周健,等.CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析[J].中华血液学杂志,2016,37(4):334-336.
[5] 夏轶姿,陈莹,王征.参芪扶正注射液联合沙利度胺对急性髓细胞白血病外周血调节性T细胞比例的影响研究[J].中华中医药学刊,2016,13(5):1215-1217.
[6] 谢晓英,史敏.沙利度胺联合去甲基化治疗方案治疗老年人急性髓系白血病临床效果观察[J].临床和实验医学杂志,2016,15(17):1673-1676.
[7] 杨艳敏,夏恒志,李一丹,等.丙戊酸钠、沙利度胺联合治疗复发难治急性白血病的临床研究[J].河北医药,2017,39(9):1379-1381.
[8] 魏旭东,艾昊,米瑞华,等.沙利度胺联合干扰素、白细胞介素-2治疗复发难治性急性髓系白血病[J].中华内科杂志,2016,55(11):875-877.
[9] 米瑞华,陈琳,魏旭东,等.干扰素α-1b、白细胞介素2联合沙利度胺方案干预治疗微小残留病阳性急性髓系白血病的疗效分析[J].中华血液学杂志,2019,40(2):111-116.
[10] 裴丽,罗艳,黄显金,等.沙利度胺的临床新应用与不良反应研究概述[J].中国药师,2016,19(5):977-980.
[2] 杨海青,邱发麒.沙利度胺对老年急性髓系白血病患者血清碱性成纤维细胞生长因子、血管内皮生长因子水平的影响[J].中国老年学杂志,2018,38(24):5936-5938.
[3] 张之南.血液病诊断与疗效标准[M].3版.北京:科学出版社,2007:103-121.
[4] 祖璎玲,张莉,周健,等.CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析[J].中华血液学杂志,2016,37(4):334-336.
[5] 夏轶姿,陈莹,王征.参芪扶正注射液联合沙利度胺对急性髓细胞白血病外周血调节性T细胞比例的影响研究[J].中华中医药学刊,2016,13(5):1215-1217.
[6] 谢晓英,史敏.沙利度胺联合去甲基化治疗方案治疗老年人急性髓系白血病临床效果观察[J].临床和实验医学杂志,2016,15(17):1673-1676.
[7] 杨艳敏,夏恒志,李一丹,等.丙戊酸钠、沙利度胺联合治疗复发难治急性白血病的临床研究[J].河北医药,2017,39(9):1379-1381.
[8] 魏旭东,艾昊,米瑞华,等.沙利度胺联合干扰素、白细胞介素-2治疗复发难治性急性髓系白血病[J].中华内科杂志,2016,55(11):875-877.
[9] 米瑞华,陈琳,魏旭东,等.干扰素α-1b、白细胞介素2联合沙利度胺方案干预治疗微小残留病阳性急性髓系白血病的疗效分析[J].中华血液学杂志,2019,40(2):111-116.
[10] 裴丽,罗艳,黄显金,等.沙利度胺的临床新应用与不良反应研究概述[J].中国药师,2016,19(5):977-980.